

FEVAXYN QUATRIFEL ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΓΙΑ ΓΑΤΕΣ

Not
authorised

- Chlamydia felis, strain Cello, Inactivated
- Felid herpesvirus 1, strain 605, Inactivated
- Feline calicivirus, strain 255, Inactivated
- Feline panleucopenia virus, strain CU4, Inactivated

Product identification

Medicine name:

FEVAXYN QUATRIFEL ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΓΙΑ ΓΑΤΕΣ

Active substance:

Chlamydia felis, strain Cello, Inactivated

Felid herpesvirus 1, strain 605, Inactivated

Feline calicivirus, strain 255, Inactivated

Feline panleucopenia virus, strain CU4, Inactivated

Target species:

Cat

Route of administration:

Intramuscular use

Subcutaneous use

Product details

Active substance and strength:

Chlamydia felis, strain Cello, Inactivated

1.69 relative potency / 1.00 millilitre(s)

Felid herpesvirus 1, strain 605, Inactivated

1.39 relative potency / 1.00 millilitre(s)

Feline calicivirus, strain 255, Inactivated

1.26 relative potency / 1.00 millilitre(s)

Feline panleucopenia virus, strain CU4, Inactivated

8.50 relative potency / 1.00 millilitre(s)

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Cat

- Not applicable. no withdrawal period

Subcutaneous use:

-

Cat

- Not applicable. no withdrawal period

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI06AL02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Surrendered

Authorised in:

Greece

Package description:

Available only in Greek

Available only in Greek

Available only in Greek

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Complete application (stand-alone)

Marketing authorisation holder:

Zoetis Hellas S.A.

Marketing authorisation date:

20/04/1993

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

National Organization For Medicines

Authorisation number:

20535/17/23-07-2018/K-0214602

Date of authorisation status change:

13/05/2025

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet